HIGHBuilt-inPipeline
BIM-IOL System
“10-K Item 1A: 'We are substantially dependent on the success of our lead product candidate, our BIM-IOL System, which is currently in clinical trials.'”
SGP · Concentration risk · 10-K extracted
SpyGlass Pharma (SGP) concentration risks
Updated
The most significant concentration SpyGlass Pharma discloses is BIM-IOL System, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: SpyGlass Pharma’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 1 disclosed concentration
HIGH1
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-07-06SpyGlass Pharma's concentration risk mirrors that of other clinical-stage medical device companies: the business is substantially dependent on the success of its lead product candidate, the BIM-IOL System, which is currently in clinical trials. This is a structural, single-asset dependency rather than a customer or supplier relationship — the risk sits at the core of the company's business model itself. Because the company has no other disclosed product candidate to diversify against, a delay, negative trial outcome, or regulatory setback for the BIM-IOL System would have a direct and outsized effect on the company's prospects, with no alternative program to offset the impact. No customer, geographic, or supplier concentration is disclosed in the cited claims, making this single-candidate dependency the sole named concentration risk and, by extension, the primary determinant of the investment case. As with any pre-commercial, single-asset company, this concentration should be treated as a structural feature of the business model rather than an incidental or easily mitigated risk, and near-term clinical or regulatory catalysts for the BIM-IOL System are likely to be the dominant driver of the verdict.
For the engine’s reasoning on SGP’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Biotechnology
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| ABUS | Arbutus Biopharma Corporation | 1 | 1 | 0 | 2 |
| ABSI | Absci Corporation | 1 | 0 | 0 | 1 |
| SGP● | SpyGlass Pharma, Inc. | 1 | 0 | 0 | 1 |
| ABCL | AbCellera Biologics Inc. | 0 | 0 | 0 | 0 |
| ACHV | Achieve Life Sciences, Inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.